Century <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces Major Workforce Reduction and Executive Departures Amid Corporate Reorganization
Century Therapeutics Inc. has announced a significant corporate reorganization aiming to streamline operations and focus on high-potential programs. On July 1, 2025, the company's Board of Directors approved a reduction in force that will see the employee headcount decrease by approximately 51%. This measure is expected to incur approximately $3.7 million in severance and other termination-related costs, with the process anticipated to be largely completed by the end of the third quarter of 2025. Additionally, the company has announced the departures of Chief Financial Officer Morgan Conn, Ph.D., effective July 11, 2025, and Chief Development Officer Adrienne Farid, Ph.D., effective July 31, 2025, as part of this restructuring. Douglas Carr, currently the Senior Vice President of Finance, will assume the role of interim Principal Financial Officer following Dr. Conn's departure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-066091), on July 07, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。